Nov. 4 at 5:02 AM
$SANA not even in the same ballpark as Sarepta. kind of annoying seeing SANA's moves correlating with gene editing stocks like PRME for example. Yea, SANA uses gene editing, but their main focus, the islets for T1D is really a tissue therapy. It's kind of its own unique thing. Yea, they have fusogen for in vivo gene editing (which by the way, SANA CEO mentioned seems to potentially avoid liver toxicity problems that companies using LNP and AAV for in vivo gene editing are having, e.g. SRPT, NTLA), but the replacement islets are really a unique therapy in a class of its own. Doesn't make a ton of sense to me to blindly group SANA with other gene editing stocks. The risks and potential side effects of the replacement islets are completely different from say in vivo gene editing. Anyways, my SANA bag is heavy with profits and I've done my due diligence, far cry from gambling. This person is obviously spouting nonsense, just look at their posts. Must be short XBI or IBB this year, lol.
